NEWS: Sen. Schiff, Rep. Auchincloss Demand Answers on Top Trump Administration Health Advisor’s Conflicts of Interest

Bicameral effort seeks more information on top advisor’s financial stakes in company that stands to benefit from the Trump administration’s health policies
Washington, D.C. —Today, U.S. Senator Adam Schiff (D-Calif.) and Congressman Jake Auchincloss (D-Mass.)demandedanswers regarding former special government employee and senior advisor to the Secretary of the Department of Health and Human Services (HHS) Calley Means’s role in helping craft  “Make America Healthy Again” (MAHA) policies, and raised concerns about Means’s financial  interests as co-founder of the health care company, True Medicine (TrueMed).
In a letter to White House Chief of Staff Susie Wiles and HHS Secretary Robert F. Kennedy Jr., the lawmakers call out Means’s abuse of his role at HHS, advising on health policies that ultimately would benefit his business interests.
“The lack of communication from the administration is of great concern and we now write with bicameral interest in assuring the American people that their policymakers took the necessary steps to avoid conflicts of interest. Although recent reports indicate that Mr. Means has departed from his role in the administration, taxpayers and families deserve assurance that Mr. Means’s prior involvement in policy had been in the interests of science and public health, not in interest of his business and personal financial gain,”the lawmakers wrote.
“Given the pattern of self-dealing and conflicts of interest throughout this administration, the public deserve to know whether Mr. Means and his business, TrueMed, operated ethically. It is therefore incumbent upon the Secretary and the White House, as Mr. Means’s former supervisors, to clarify his role and verify compliance with federal conflicts of interest, ethics, and reporting requirements,”the lawmakers wrote.
The full text of the letter can be foundhereand below.
We write to express grave concern regarding Calley Means’s former role as a White House Advisor to theSecretary of the Department of Health and Human Services (HHS) while he retained financial interests in True Medicine Inc. (TrueMed), which stood to benefit from the Trump Administration’s “Make America Healthy Again” policies that Mr. Means helped craft.
Mr. Means has publicly touted his role as a leading policymaker behind the Trump Administration’s “Make America Healthy Again” (MAHA) initiative, including the May 2025 Make America Healthy Again report and the September 2025 Make Our Children Healthy Again (MCHA) strategy. Mr. Means’s company, TrueMed, appears to have benefited greatly from MAHA policies, including expansions to products eligible for purchase using tax-advantaged spending and an expansion of allowable uses of health savings accounts (HSAs) and flexible savings accounts (FSAs). For example, TrueMed now advertises as HSA-eligible the “Alpha JX2 Bidet,” which the company claims aids autoimmune, digestive, and joint health. Thus, recently enacted policies under HHS’s MAHA strategy that purport to fight chronic disease and the obesity epidemic have conveniently ended up in windfalls for people in MAHA’s inner circle like Mr. Means.
To get clarity on the steps Mr. Means took to avoid conflicts of interest and to act in the best interest of the American people, Representative Auchincloss sent a letter to Mr. Means on the subject, which has yet to receive a response. Furthermore, HHS Secretary Kennedy refused to offer any assurances or clarifications when asked about Mr. Means’s role in his testimony before Congress on June 24, 2025. Similar requests from Senator Schiff to this administration regarding special government employees’ (SGE) compliance with federal ethics laws have also gone unanswered.
The lack of communication from the administration is of great concern and we now write with bicameralinterest in assuring the American people that their policymakers have taken the necessary steps to avoidconflicts of interest. Although recent reports indicate that Mr. Means has departed from his role in theadministration, taxpayers and families deserve assurance that Mr. Means’s prior involvement in policy had been in the interests of science and public health, not in interest of his business and personal financial gain.
Given the pattern of self-dealing and conflicts of interest throughout this administration,8the public deserve to know whether Mr. Means and his business, TrueMed, operated ethically. It is therefore incumbent upon the Secretary and the White House, as Mr. Means’s former supervisors, to clarify his former role and ensure compliance with federal conflicts of interest, ethics, and reporting requirements.
In order to fulfill Congress’s constitutional obligation to perform oversight over federal agencies, we request your responses to the following questions regarding the steps taken to ensure an ethical and legal separation of interests and proprietary information no later than Friday, November 14, 2025.
MAHA Report and the MCHA Strategy:
Role of a Special Government Employee:
SGEs are historically excluded from policy decision-making, serving as strictly advisory individuals within an administration. Additionally, SGEs are only appointed if they are expected to serve no more than 130 days. If they “unexpectedly” serve over 130 days, they remain an SGE for the remainder of that 365-day period. However, the Trump Administration has greatly expanded the use and scope of SGEs. There is widespread concern that the Trump Administration’s misuse of the SGE designation betrays public trust and circumvents ethics requirements pertaining to self-dealing and transparency.
Mr. Means is one example of an SGE who has served in an unprecedented expansive capacity in both influence and duration. Mr. Means was appointed on March 18, 2025, which would mean his statutory 130-day period as an SGE should have ended around July 25, 2025. On October 30, 2025, Mr. Means shared that he left the administration “about a month ago” and that “he took time off earlier in the year,” in order to meet the statutory limit. Without verification of these claims, it still raises concern that Mr. Means’s original appointment may not have been “based on a good faith” estimate as is required under long-standing executive branch precedent.
Ethics Requirements for Federal Employees:
As an SGE, Mr. Means was subject to public financial disclosure requirements if he was compensated at a rate equal to the statutory threshold defined in the Ethics in Government Act. Additionally, unless a senior administration official, in consultation with the Office of Government Ethics, provided a written waiver prior to Mr. Means’s appointment as an SGE, Mr. Means may have violated federal criminal conflict of interest law by undertaking acts otherwise prohibited by law while retaining his financial stake in his company, TrueMed. In what appears to be an attempt to avoid such restrictions, Mr. Means has purportedly not received any compensation from the federal government. Therefore, his compliance with federal conflict of interest laws and related obligations remains unknown to Congress and the public.
###